Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Bernstein analyst Lee Hambright lowered the firm’s price target on Johnson & Johnson to $158 from $160 and keeps a Market Perform rating on ...
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...